Investor · 3 deals
Every published round Bezos Expeditions took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Advanced Machine Intelligence | Seed | Mar 2026 | $1b | Lead | rumourwithai.com | |
| Synchron | Series D+ | Nov 2025 | $305m | Participant | Startup Daily (3 Feb 2026), Startup Daily (23 Dec 2025), SmartCompany (23 Dec 2025), Startup Daily (9 Nov 2025), Startup Daily (7 Nov 2025), SmartCompany (7 Nov 2025) | |
| Synchron | Series C | 16 Dec 2022 | $110m | Participant | Startup Daily (7 Nov 2025), Techboard, SmartCompany (16 Dec 2022), Startup Daily (16 Dec 2022), SmartCompany (16 Dec 2022) |
Companies Bezos Expeditions has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Advanced Machine Intelligence | Mar 2026, Seed | 1 | 1 | |
| Synchron | 16 Dec 2022, Series C | 2 | 0 |
Fund closes reported for Bezos Expeditions, as distinct from the investments it has made.
Companies Bezos Expeditions has backed that another company then bought. An exit for the holding, not a deal Bezos Expeditions did.
Stories naming Bezos Expeditions. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Manufacturing roundup: Boeing ends local 747 parts, ASM signs a rare earths supply deal, Melt Ventures launches a seed fund raise, Thales trials dockyard tracking, and Synchron closes a large round.
Weekly roundup covering 14 startup raises totalling over $260 million, headlined by Synchron's $110 million round, plus Roller's shareholder liquidity payout, Partly's record New Zealand Series A, and several government grants.
Also Startup Daily·Startup Daily·Techboard·SmartCompany·SmartCompany·Startup Daily·SmartCompany·Startup News (WA)·Startup News (WA)
Brain-computer interface maker Synchron has closed an oversubscribed Series C, with proceeds earmarked for product development and clinical trials; its co-founder downplays any rivalry with Neuralink.